Switch to:
Also traded in: Denmark, Germany, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 19.07
NVO's Cash to Debt is ranked lower than
54% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. NVO: 19.07 )
Ranked among companies with meaningful Cash to Debt only.
NVO' s Cash to Debt Range Over the Past 10 Years
Min: 0.29  Med: 2.85 Max: 67.3
Current: 19.07
0.29
67.3
Equity to Asset 0.51
NVO's Equity to Asset is ranked lower than
70% of the 705 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. NVO: 0.51 )
Ranked among companies with meaningful Equity to Asset only.
NVO' s Equity to Asset Range Over the Past 10 Years
Min: 0.51  Med: 0.66 Max: 0.73
Current: 0.51
0.51
0.73
Interest Coverage 284.18
NVO's Interest Coverage is ranked lower than
60% of the 393 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NVO: 284.18 )
Ranked among companies with meaningful Interest Coverage only.
NVO' s Interest Coverage Range Over the Past 10 Years
Min: 9.18  Med: 40.73 Max: 884.41
Current: 284.18
9.18
884.41
F-Score: 8
Z-Score: 16.75
M-Score: -2.20
WACC vs ROIC
12.22%
142.60%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 43.61
NVO's Operating margin (%) is ranked higher than
95% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -66.05 vs. NVO: 43.61 )
Ranked among companies with meaningful Operating margin (%) only.
NVO' s Operating margin (%) Range Over the Past 10 Years
Min: 21.38  Med: 32.40 Max: 45.81
Current: 43.61
21.38
45.81
Net-margin (%) 32.30
NVO's Net-margin (%) is ranked higher than
93% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -68.08 vs. NVO: 32.30 )
Ranked among companies with meaningful Net-margin (%) only.
NVO' s Net-margin (%) Range Over the Past 10 Years
Min: 16.65  Med: 24.74 Max: 32.3
Current: 32.3
16.65
32.3
ROE (%) 86.46
NVO's ROE (%) is ranked higher than
99% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -31.46 vs. NVO: 86.46 )
Ranked among companies with meaningful ROE (%) only.
NVO' s ROE (%) Range Over the Past 10 Years
Min: 22.36  Med: 42.79 Max: 79.9
Current: 86.46
22.36
79.9
ROA (%) 42.22
NVO's ROA (%) is ranked higher than
99% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -26.29 vs. NVO: 42.22 )
Ranked among companies with meaningful ROA (%) only.
NVO' s ROA (%) Range Over the Past 10 Years
Min: 14.9  Med: 25.96 Max: 41.29
Current: 42.22
14.9
41.29
ROC (Joel Greenblatt) (%) 181.83
NVO's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. NVO: 181.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NVO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 36.68  Med: 87.94 Max: 178.92
Current: 181.83
36.68
178.92
Revenue Growth (3Y)(%) 14.00
NVO's Revenue Growth (3Y)(%) is ranked higher than
67% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. NVO: 14.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NVO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -46.3  Med: 14.00 Max: 127.9
Current: 14
-46.3
127.9
EBITDA Growth (3Y)(%) 17.60
NVO's EBITDA Growth (3Y)(%) is ranked higher than
73% of the 497 Companies
in the Global Biotechnology industry.

( Industry Median: -0.30 vs. NVO: 17.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NVO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -44.4  Med: 16.70 Max: 130.3
Current: 17.6
-44.4
130.3
EPS Growth (3Y)(%) 20.30
NVO's EPS Growth (3Y)(%) is ranked higher than
77% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. NVO: 20.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NVO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 5.6  Med: 20.40 Max: 36.9
Current: 20.3
5.6
36.9
» NVO's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-04-30)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

NVO Guru Trades in Q2 2015

Tom Gayner 1,075,000 sh (unchged)
Murray Stahl 7,740 sh (unchged)
Ruane Cunniff 81,800 sh (-0.30%)
Mario Gabelli 6,545 sh (-2.31%)
Ken Fisher 12,295,864 sh (-2.88%)
Jim Simons 14,087,000 sh (-2.94%)
» More
Q3 2015

NVO Guru Trades in Q3 2015

Murray Stahl 7,827 sh (+1.12%)
Tom Gayner 1,075,000 sh (unchged)
Ruane Cunniff 81,320 sh (-0.59%)
Ken Fisher 11,652,268 sh (-5.23%)
Mario Gabelli 6,170 sh (-5.73%)
Jim Simons 13,171,000 sh (-6.50%)
» More
Q4 2015

NVO Guru Trades in Q4 2015

Mario Gabelli 6,210 sh (+0.65%)
Murray Stahl 7,827 sh (unchged)
Tom Gayner 1,075,000 sh (unchged)
Ruane Cunniff 81,320 sh (unchged)
Spiros Segalas 7,362,676 sh (unchged)
Ken Fisher 11,447,413 sh (-1.76%)
Jim Simons 12,898,800 sh (-2.07%)
» More
Q1 2016

NVO Guru Trades in Q1 2016

Murray Stahl 7,787 sh (-0.51%)
Ken Fisher 11,178,809 sh (-2.35%)
Spiros Segalas 6,179,837 sh (-16.07%)
» More
» Details

Insider Trades

Latest Guru Trades with NVO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Novo Nordisk A/S

Jim Simons' Five Most-Heavily Weighted Holdings Colgate-Palmolive tops the list
More than 30 years ago, Jim Simons (Trades, Portfolio) founded investment firm Renaissance Technologies. Today it is one of the most successful hedge funds in the world. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 27.37
NVO's P/E(ttm) is ranked higher than
55% of the 238 Companies
in the Global Biotechnology industry.

( Industry Median: 30.50 vs. NVO: 27.37 )
Ranked among companies with meaningful P/E(ttm) only.
NVO' s P/E(ttm) Range Over the Past 10 Years
Min: 12.13  Med: 24.04 Max: 35.76
Current: 27.37
12.13
35.76
Forward P/E 21.55
NVO's Forward P/E is ranked lower than
56% of the 87 Companies
in the Global Biotechnology industry.

( Industry Median: 17.92 vs. NVO: 21.55 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 27.37
NVO's PE(NRI) is ranked higher than
55% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 31.00 vs. NVO: 27.37 )
Ranked among companies with meaningful PE(NRI) only.
NVO' s PE(NRI) Range Over the Past 10 Years
Min: 12.03  Med: 24.02 Max: 35.76
Current: 27.37
12.03
35.76
Price/Owner Earnings (ttm) 29.45
NVO's Price/Owner Earnings (ttm) is ranked higher than
56% of the 143 Companies
in the Global Biotechnology industry.

( Industry Median: 33.75 vs. NVO: 29.45 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
NVO' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 13.81  Med: 29.40 Max: 68.66
Current: 29.45
13.81
68.66
P/B 20.49
NVO's P/B is ranked lower than
93% of the 843 Companies
in the Global Biotechnology industry.

( Industry Median: 3.49 vs. NVO: 20.49 )
Ranked among companies with meaningful P/B only.
NVO' s P/B Range Over the Past 10 Years
Min: 3.66  Med: 7.77 Max: 31.9
Current: 20.49
3.66
31.9
P/S 8.85
NVO's P/S is ranked higher than
57% of the 674 Companies
in the Global Biotechnology industry.

( Industry Median: 11.42 vs. NVO: 8.85 )
Ranked among companies with meaningful P/S only.
NVO' s P/S Range Over the Past 10 Years
Min: 2.8  Med: 5.81 Max: 11.01
Current: 8.85
2.8
11.01
PFCF 29.94
NVO's PFCF is ranked higher than
53% of the 114 Companies
in the Global Biotechnology industry.

( Industry Median: 30.93 vs. NVO: 29.94 )
Ranked among companies with meaningful PFCF only.
NVO' s PFCF Range Over the Past 10 Years
Min: 12.07  Med: 24.36 Max: 47.08
Current: 29.94
12.07
47.08
POCF 24.98
NVO's POCF is ranked higher than
50% of the 175 Companies
in the Global Biotechnology industry.

( Industry Median: 25.07 vs. NVO: 24.98 )
Ranked among companies with meaningful POCF only.
NVO' s POCF Range Over the Past 10 Years
Min: 9.91  Med: 19.29 Max: 32.54
Current: 24.98
9.91
32.54
EV-to-EBIT 21.62
NVO's EV-to-EBIT is ranked higher than
54% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 24.70 vs. NVO: 21.62 )
Ranked among companies with meaningful EV-to-EBIT only.
NVO' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.2  Med: 16.90 Max: 25.7
Current: 21.62
9.2
25.7
EV-to-EBITDA 20.28
NVO's EV-to-EBITDA is ranked higher than
50% of the 275 Companies
in the Global Biotechnology industry.

( Industry Median: 20.64 vs. NVO: 20.28 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.2  Med: 16.40 Max: 25.1
Current: 20.28
8.2
25.1
PEG 1.56
NVO's PEG is ranked higher than
63% of the 84 Companies
in the Global Biotechnology industry.

( Industry Median: 2.23 vs. NVO: 1.56 )
Ranked among companies with meaningful PEG only.
NVO' s PEG Range Over the Past 10 Years
Min: 0.48  Med: 1.24 Max: 5.17
Current: 1.56
0.48
5.17
Shiller P/E 55.70
NVO's Shiller P/E is ranked lower than
51% of the 51 Companies
in the Global Biotechnology industry.

( Industry Median: 54.88 vs. NVO: 55.70 )
Ranked among companies with meaningful Shiller P/E only.
NVO' s Shiller P/E Range Over the Past 10 Years
Min: 22.8  Med: 42.52 Max: 67.58
Current: 55.7
22.8
67.58
Current Ratio 1.35
NVO's Current Ratio is ranked lower than
85% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. NVO: 1.35 )
Ranked among companies with meaningful Current Ratio only.
NVO' s Current Ratio Range Over the Past 10 Years
Min: 1.35  Med: 2.23 Max: 2.45
Current: 1.35
1.35
2.45
Quick Ratio 1.04
NVO's Quick Ratio is ranked lower than
86% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. NVO: 1.04 )
Ranked among companies with meaningful Quick Ratio only.
NVO' s Quick Ratio Range Over the Past 10 Years
Min: 1.04  Med: 1.45 Max: 1.91
Current: 1.04
1.04
1.91
Days Inventory 279.54
NVO's Days Inventory is ranked lower than
84% of the 440 Companies
in the Global Biotechnology industry.

( Industry Median: 120.79 vs. NVO: 279.54 )
Ranked among companies with meaningful Days Inventory only.
NVO' s Days Inventory Range Over the Past 10 Years
Min: 246.45  Med: 292.48 Max: 343.56
Current: 279.54
246.45
343.56
Days Sales Outstanding 52.37
NVO's Days Sales Outstanding is ranked higher than
61% of the 603 Companies
in the Global Biotechnology industry.

( Industry Median: 66.24 vs. NVO: 52.37 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.09  Med: 51.24 Max: 53.6
Current: 52.37
45.09
53.6
Days Payable 111.09
NVO's Days Payable is ranked higher than
67% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 63.23 vs. NVO: 111.09 )
Ranked among companies with meaningful Days Payable only.
NVO' s Days Payable Range Over the Past 10 Years
Min: 65.17  Med: 93.12 Max: 124.07
Current: 111.09
65.17
124.07

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.74
NVO's Dividend Yield is ranked higher than
68% of the 208 Companies
in the Global Biotechnology industry.

( Industry Median: 1.34 vs. NVO: 1.74 )
Ranked among companies with meaningful Dividend Yield only.
NVO' s Dividend Yield Range Over the Past 10 Years
Min: 0.79  Med: 1.51 Max: 2.47
Current: 1.74
0.79
2.47
Dividend Payout 0.37
NVO's Dividend Payout is ranked lower than
58% of the 112 Companies
in the Global Biotechnology industry.

( Industry Median: 0.33 vs. NVO: 0.37 )
Ranked among companies with meaningful Dividend Payout only.
NVO' s Dividend Payout Range Over the Past 10 Years
Min: 0.13  Med: 0.27 Max: 0.45
Current: 0.37
0.13
0.45
Dividend Growth (3y) 21.30
NVO's Dividend Growth (3y) is ranked higher than
79% of the 87 Companies
in the Global Biotechnology industry.

( Industry Median: 5.60 vs. NVO: 21.30 )
Ranked among companies with meaningful Dividend Growth (3y) only.
NVO' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 22.70 Max: 49.4
Current: 21.3
0
49.4
Forward Dividend Yield 1.71
NVO's Forward Dividend Yield is ranked higher than
67% of the 190 Companies
in the Global Biotechnology industry.

( Industry Median: 1.27 vs. NVO: 1.71 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 8.77
NVO's Yield on cost (5-Year) is ranked higher than
96% of the 255 Companies
in the Global Biotechnology industry.

( Industry Median: 1.56 vs. NVO: 8.77 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
NVO' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 3.98  Med: 7.61 Max: 12.45
Current: 8.77
3.98
12.45
3-Year Average Share Buyback Ratio 2.20
NVO's 3-Year Average Share Buyback Ratio is ranked higher than
97% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: -10.70 vs. NVO: 2.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -92.3  Med: 2.20 Max: 49.1
Current: 2.2
-92.3
49.1

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 92.98
NVO's Price/Net Current Asset Value is ranked lower than
97% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 5.40 vs. NVO: 92.98 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NVO' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 11.62  Med: 23.76 Max: 100.73
Current: 92.98
11.62
100.73
Price/Tangible Book 21.46
NVO's Price/Tangible Book is ranked lower than
89% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. NVO: 21.46 )
Ranked among companies with meaningful Price/Tangible Book only.
NVO' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.14  Med: 5.90 Max: 23.2
Current: 21.46
3.14
23.2
Price/Projected FCF 3.81
NVO's Price/Projected FCF is ranked lower than
53% of the 172 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. NVO: 3.81 )
Ranked among companies with meaningful Price/Projected FCF only.
NVO' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.45  Med: 2.96 Max: 7.38
Current: 3.81
1.45
7.38
Price/DCF (Earnings Based) 0.96
NVO's Price/DCF (Earnings Based) is ranked higher than
61% of the 18 Companies
in the Global Biotechnology industry.

( Industry Median: 1.16 vs. NVO: 0.96 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.52
NVO's Price/Median PS Value is ranked lower than
75% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. NVO: 1.52 )
Ranked among companies with meaningful Price/Median PS Value only.
NVO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.5  Med: 0.88 Max: 1.65
Current: 1.52
0.5
1.65
Price/Peter Lynch Fair Value 1.09
NVO's Price/Peter Lynch Fair Value is ranked higher than
74% of the 61 Companies
in the Global Biotechnology industry.

( Industry Median: 1.87 vs. NVO: 1.09 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
NVO' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.27  Med: 1.13 Max: 3.78
Current: 1.09
0.27
3.78
Price/Graham Number 5.11
NVO's Price/Graham Number is ranked lower than
76% of the 292 Companies
in the Global Biotechnology industry.

( Industry Median: 2.51 vs. NVO: 5.11 )
Ranked among companies with meaningful Price/Graham Number only.
NVO' s Price/Graham Number Range Over the Past 10 Years
Min: 1.56  Med: 2.76 Max: 5.52
Current: 5.11
1.56
5.52
Earnings Yield (Greenblatt) (%) 4.56
NVO's Earnings Yield (Greenblatt) (%) is ranked higher than
87% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. NVO: 4.56 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NVO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.9  Med: 5.90 Max: 10.8
Current: 4.56
3.9
10.8
Forward Rate of Return (Yacktman) (%) 28.12
NVO's Forward Rate of Return (Yacktman) (%) is ranked higher than
74% of the 107 Companies
in the Global Biotechnology industry.

( Industry Median: 14.45 vs. NVO: 28.12 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
NVO' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 7.5  Med: 23.20 Max: 38.6
Current: 28.12
7.5
38.6

More Statistics

Revenue(Mil) $16279
EPS $ 2.04
Beta0.39
Short Percentage of Float0.11%
52-Week Range $46.17 - 60.34
Shares Outstanding(Mil)2600.00

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 19,767 20,730 22,222
EPS($) 2.62 2.90 3.14
EPS without NRI($) 2.62 2.90 3.14

Business Description

Industry: Biotechnology » Biotechnology
Compare:XSWX:RO, NAS:GILD, NAS:AMGN, NAS:CELG, NAS:BIIB » details
Traded in other countries:NOVO B.Denmark, NOVA.Germany, NOVOB.Switzerland, 0QIU.UK, NONOF.USA,
Novo-Nordisk A/S is a healthcare company incorporated on November 28, 1931 in Denmark. The Company has diabetes product portfolios, including new generation insulins, a full portfolio of modern insulins as well as a human once-daily GLP-1 analog. In addition, it also has a position within haemophilia care, growth hormone therapy and hormone replacement therapy, and Company's first product to treat obesity, Saxenda, was approved in the United States in December 2014. The Company manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments: diabetes care and biopharmaceuticals. The diabetes care segment covers insulins, GLP-1, other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. On December 23, 2014, the GLP-1 agonist liraglutide was approved in the United States in a 3 mg dose for weight management. The trade name for this product will be Saxenda and launch is planned for the first half of 2015. The biopharmaceuticals segment covers the therapy areas of haemophilia care, growth hormone therapy and hormone replacement therapy. In 2014 the Company announced that all activities within inflammation will be discontinued. The Company's insulin and other pharmaceutical products are marketed and distributed through subsidiaries, distributors and independent agents with responsibility for specific geographical areas. The important markets are North America, China, Japan and the major European countries. In addition there is an increasing contribution to its total sales from key markets in the sales region International Operations such as Algeria, Turkey, Australia, India, Argentina, Brazil and Russia.
» More Articles for NVO

Headlines

Articles On GuruFocus.com
Jim Simons' Top Holdings Include VeriSign, Chipotle Dec 15 2015 
Value Investing in BioPharma Nov 18 2015 
Jim Simons' Five Most-Heavily Weighted Holdings Oct 21 2015 
Ken Fisher Reduces Stake in Toyota, Increases Position in Anheuser-Busch Oct 20 2015 
Jim Simons and Ken Fisher Decrease Exposure on Novo Nordisk A/S Sep 14 2015 
Nintai Returns: Q2 2015 Jul 01 2015 
Leith Wheeler Investment Funds First Quarter 2015 Review Jun 15 2015 
Jim Simons' Top 3 Positions and One That Doubled Return Jun 10 2015 
Weekly 52-Week Highs Highlight: ALTR, AIG, LUX, NVO, EXPE May 03 2015 
MannKind Looks Good For Long Term Investors Apr 29 2015 

More From Other Websites
3:58 am Novo Nordisk beats by DKK0.15; revs in-line; reaffirms FY16 outlook Apr 29 2016
Novo Nordisk increased adjusted operating profit by 10% in local currencies in the first quarter of... Apr 29 2016
Novo Nordisk A/S - Share repurchase programme Apr 28 2016
Novo Nordisk A/S - aktietilbagekøbsprogram Apr 28 2016
Novo Nordisk A/S - Total number of voting rights and share capital in Novo Nordisk A/S as of 28... Apr 28 2016
Semaglutide significantly reduces the risk of major adverse cardiovascular events in the SUSTAIN 6... Apr 28 2016
Stocks Are Mixed as Oil Jumps 3% Apr 26 2016
5 Large-Cap Stocks to Buy as the S&P Makes New Highs Apr 21 2016
Novo Nordisk plans to invest more than 100 million euros in production plants in Chartres, France Apr 21 2016
Novo Nordisk A/S - Reduction of the share capital Apr 18 2016
Novo Nordisk A/S - Share repurchase programme Apr 18 2016
How Much Potential Does Saxenda Hold for Novo? Apr 17 2016
Long views, deep pockets: Danish foundations keep pharma groups healthy Apr 17 2016
Long views, deep pockets: Danish foundations keep pharma groups healthy Apr 16 2016
Victoza to Fuel Growth for Novo Nordisk Apr 15 2016
Moody's: Broad pipeline gains bode well for mid-term revenue and earnings of European Pharma Apr 15 2016
Analyzing Novo’s Haemophilia and Growth Hormone Portfolio Apr 13 2016
How Is Novo Nordisk Doing in the Diabetes Space? Apr 12 2016
Novo Nordisk A/S - Share repurchase programme Apr 11 2016
Novo Nordisk A/S: Johannesburg joins Cities Changing Diabetes Apr 08 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK